Subscribe to AHPA Updates to be notified of upcoming AHPA events.
Congress passed a Farm Bill in 2018 that included historic provisions to legalize hemp, the low THC cultivars of the Cannabis sativa L. species. This landmark legislation changes how hemp and hemp-derived products like cannabidiol (CBD) are regulated in the U.S. To help the herbal products industry understand the new regulatory landscape, AHPA has expanded this Status Report and to answer industry questions about the new legal landscape.
AHPA partnered with the Hemp Industries Association (HIA) to present a webinar on Feb. 21 aimed at helping the herbal products industry understand the evolving regulatory landscape for hemp and cannabidiol (CBD) products.
Attend this webinar to learn how to successfully traverse the NDI notification process and avoid common pitfalls that can result in FDA objections.
Recorded September 20, 2018 -- Duration: 2 hours
Recorded May 22, 2018 -- Member cost: $150. Nonmember cost: $350.
This two-part webinar provides an update on the elements of current Good Manufacturing Practice (cGMP) regulations (21 CFR 111) that have been the primary focus of recent FDA inspections. Experts also provide strategies to respond to an FDA 483 in order to avoid a warning letter.
2019 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.